Will the Phase 2 trial "A Study of DM002 in Patients With Advanced Solid Tumors" reach primary completion on or before Oct 8, 2027?

Resolves Yes if ClinicalTrials.gov record NCT06751329 (Xadcera Biopharmaceutical (Suzhou) Co., Ltd.) shows an actual primary completion date on or before Oct 8, 2027. Registered date at generation: Oct 8, 2027.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Oct 8, 2027, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.